We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+35.64%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$291M
AUM Growth
+$25.4M
Cap. Flow
-$37.9M
Cap. Flow %
-13.02%
Top 10 Hldgs %
53.99%
Holding
96
New
7
Increased
8
Reduced
27
Closed
15

Top Buys

Rank Stock Value
1
PRQR icon
ProQR Therapeutics
PRQR
+$6.64M
2
AFMD
Affimed
AFMD
+$3.03M
3
STIM icon
Neuronetics
STIM
+$1.8M
4
OTIC
Otonomy, Inc.
OTIC
+$1.15M
5
KURA icon
Kura Oncology
KURA
+$1.03M

Top Sells

Rank Stock Value
1
ALDR
Alder Biopharmaceuticals
ALDR
+$12M
2
WVE icon
Wave Life Sciences
WVE
+$3.94M
3
ASND icon
Ascendis Pharma A/S
ASND
+$3.6M
4
APLS
Apellis Pharmaceuticals
APLS
+$3.57M
5
ARDX icon
Ardelyx
ARDX
+$2.31M

Sector Composition

Rank Sector Weight
1 Healthcare 91.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASLN
76
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$239K 0.08%
+2,942
New +$210K
URGN icon
77
UroGen Pharma
URGN
$1.88B
$133K 0.05%
3,987
-11,013
-73% -$301K
LCTX icon
78
Lineage Cell Therapeutics
LCTX
$277M
$85K 0.03%
95,000
– –
EVLO
79
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
$44K 0.02%
536
-464
-46% -$51.9K
ALDX icon
80
Aldeyra Therapeutics
ALDX
$92.3M
– –
-50,000
Closed -$264K
BTAI icon
81
BioXcel Therapeutics
BTAI
$26.2M
– –
-7,969
Closed -$898K
CDTX
82
DELISTED
Cidara Therapeutics
CDTX
– –
-5,000
Closed -$199K
ORMP icon
83
Oramed Pharmaceuticals
ORMP
$180M
– –
-16,000
Closed -$51K
SPRO icon
84
Spero Therapeutics
SPRO
$66.6M
– –
-39,395
Closed -$418K
RNTX
85
Rein Therapeutics
RNTX
$63.8M
– –
-4,975
Closed -$67K
NVRO
86
DELISTED
NEVRO CORP.
NVRO
– –
-21,210
Closed -$1.82M
VIRX
87
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-26,314
Closed -$663K
CBAY
88
DELISTED
Cymabay Therapeutics
CBAY
– –
-349,996
Closed -$1.79M
KRTX
89
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-11,192
Closed -$183K
BLCM
90
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
– –
-20,000
Closed -$210K
OBSV
91
DELISTED
ObsEva SA Ordinary Shares
OBSV
– –
-64,231
Closed -$535K
FOMX
92
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
– –
-305,500
Closed -$929K
DERM
93
DELISTED
Dermira, Inc.
DERM
– –
-104,000
Closed -$665K
ALDR
94
DELISTED
Alder Biopharmaceuticals
ALDR
– –
-636,013
Closed -$12M
1 2 3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return

DAFNA Capital Management's Q4 2019 Portfolio in Review

As of Q4 2019, DAFNA Capital Management held 96 positions worth $291M, up 9.6% from $266M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

DAFNA Capital Management withdrew a net $37.9M in Q4 2019, closing 15 positions and reducing 27 holdings. Its most notable exit was Alder Biopharmaceuticals, an estimated $12M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 92% a quarter earlier.

Against the trend, DAFNA Capital Management opened a new position in Affimed worth $3.11M.

  • DAFNA Capital Management's largest Q4 2019 buy was Affimed: 113,356 shares worth $3.11M.
  • DAFNA Capital Management added most to ProQR Therapeutics in Q4 2019, an estimated $6.64M increase.
  • DAFNA Capital Management's biggest Q4 2019 reduction was Wave Life Sciences, cutting an estimated $3.94M.
  • DAFNA Capital Management fully exited Alder Biopharmaceuticals in Q4 2019, selling an estimated $12M.
  • DAFNA Capital Management's ten largest holdings make up 54% of its $291M portfolio in Q4 2019.
  • DAFNA Capital Management opened 7 new positions and closed 15 in Q4 2019.
  • DAFNA Capital Management's portfolio value rose 9.6% quarter-over-quarter to $291M.

Based on DAFNA Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.